Stress and anxiety are among the most common mental health conditions worldwide, affecting millions of people with persistent fear, excessive worry, and physical, behavioral, and cognitive symptoms that can significantly impact daily life. While available therapies provide important treatment options, there remains continued interest in expanding therapeutic approaches for anxiety and other neurological conditions.
At Trait Biosciences, we believe that advancing cannabinoid therapeutics requires more than identifying promising cannabinoid molecules. Successful pharmaceutical development also depends on solving one of the field’s most persistent challenges: delivering cannabinoids efficiently and consistently to where they are needed in the body.
Cannabinoids have emerged as an active area of pharmaceutical research because of their interaction with the endocannabinoid system, which plays a role in regulating stress responses, emotional processing, and neuronal function. Research is exploring their potential across multiple neurological and psychiatric conditions, including anxiety. However, realizing that therapeutic potential requires delivery technologies capable of improving absorption, pharmacokinetic consistency, and tissue exposure.
Why Brain Exposure Matters
Many neurological therapies require adequate concentrations of drug to reach the brain before therapeutic effects can be achieved. As a result, researchers routinely evaluate both systemic exposure and brain exposure when developing new drug candidates.
At Trait Biosciences, our research focuses on improving these critical pharmacokinetic parameters. For cannabinoid-based drug development, improving the consistency of absorption and increasing drug availability after administration may help support more predictable pharmacokinetic profiles. These characteristics are important when optimizing dosing strategies and evaluating therapeutic responses throughout preclinical and clinical development.
Trait Biosciences’ Approach to Cannabinoid Delivery
One of the major obstacles in cannabinoid drug development is delivery. Cannabidiol (CBD) is lipophilic and water-insoluble, characteristics that can influence dissolution, gastrointestinal absorption, and overall pharmacokinetic performance. In addition, extensive first-pass metabolism reduces the amount of orally administered CBD that reaches systemic circulation.
Trait Biosciences has built its cannabinoid ingredient platform specifically to address these challenges. Our proprietary water-soluble cannabinoid technology is innovated to improve delivery characteristics while maintaining formulation flexibility for pharmaceutical development. Produced through proprietary enzymatic and chemical synthesis processes, Trait’s cannabinoids readily disperse in aqueous systems without requiring added chemicals such as emulsifiers.
Rather than relying solely on formulation strategies to improve delivery, Trait innovates the cannabinoid ingredient itself to enhance its pharmaceutical performance across multiple potential delivery routes.
CBD82S™: Innovated for Improved Brain Exposure
One example from Trait Biosciences’ platform is CBD82S™, a water-soluble cannabidiol ingredient developed to improve absorption and pharmacokinetic performance across multiple potential delivery routes, including oral, topical, inhalable, and injectable formulations.
Preclinical studies have demonstrated that CBD82S exhibits greater permeation across intestinal and buccal tissues than conventional CBD, supporting improved systemic absorption and bioavailability. Studies using CBD82S also demonstrated increased brain exposure compared with conventional CBD. Brain exposure is an important pharmacokinetic endpoint for neurological drug development because therapeutic activity depends on sufficient drug concentrations reaching central targets.
In addition to these pharmacokinetic findings, preclinical behavioral studies showed that mice receiving CBD82S demonstrated significantly reduced activity levels, findings that suggest potential calming and anxiety-reducing effects. While these results are preliminary and require further investigation, they support continued evaluation of CBD82S in future research.
These findings reflect Trait Biosciences’ broader strategy of developing cannabinoid ingredients that address pharmaceutical delivery challenges while enabling researchers to better evaluate therapeutic potential.
Looking Ahead
Continued advances in cannabinoid therapeutics will depend not only on understanding cannabinoid pharmacology but also on improving how these molecules are delivered. Better absorption, more predictable pharmacokinetics, and enhanced brain exposure can provide important advantages during drug development by supporting more consistent evaluation of therapeutic performance.
Trait Biosciences’ water-soluble cannabinoid platform innovated to address these development challenges through improved formulation characteristics and delivery performance. As research continues, technologies that improve pharmacokinetic consistency and brain exposure may help expand opportunities for the development of future cannabinoid-based therapies targeting stress and anxiety-related conditions.
References
- World Health Organization. (2025). Anxiety disorders. World Health Organization.
- Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64(1), 21–47.
- Perucca, E., & Bialer, M. (2020). Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs, 34(8), 795–800.
- Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in Pharmacology, 9(1365).
- Nakano, Y., Tajima, M., Sugiyama, E., Sato, V., & Sato, H. (2019). Development of a Novel Nanoemulsion Formulation to Improve Intestinal Absorption of Cannabidiol. Medical Cannabis and Cannabinoids, 2(1), 35–42.